Zobrazeno 1 - 10
of 534
pro vyhledávání: '"F Casellas"'
Autor:
F. Casellas, Xavier Calvet, D. Carpio, I. Vera, R. Saldaña, M. Mínguez, L. Marín, B. Juliá, GETECCU, GETEII and ACCU
Publikováno v:
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background Quality of care (QoC) is a highly important topic in inflammatory bowel disease (IBD). We recently elaborated a decalogue of QoC indicators (IQCARO-QoC) developed by IBD patients. The aim of the present study was to assess the fac
Externí odkaz:
https://doaj.org/article/44eb07a41af4471aa68bcd423fdfb84e
Autor:
G. Sarrabayrouse, A. Elias, F. Yáñez, L. Mayorga, E. Varela, C. Bartoli, F. Casellas, N. Borruel, C. Herrera de Guise, K. Machiels, S. Vermeire, C. Manichanh
Publikováno v:
mSystems, Vol 6, Iss 2 (2021)
ABSTRACT Microbiome sequence data have been used to characterize Crohn's disease (CD) and ulcerative colitis (UC). Based on these data, we have previously identified microbiomarkers at the genus level to predict CD and CD relapse. However, microbial
Externí odkaz:
https://doaj.org/article/2974d625b5e24216b1cba5690fe2589e
Publikováno v:
Franchise Law Journal, 2017 Apr 01. 36(4), 603-626.
Externí odkaz:
https://www.jstor.org/stable/26421664
Autor:
X Serra-Ruiz, C Herrera-de Guise, J Esperalba, L Mayorga Ayala, E Céspedes Martínez, V Robles Alonso, F Casellas, Z Pérez Martínez, E Oller, N Borruel Sainz
Publikováno v:
Journal of Crohn's and Colitis. 17:i354-i356
Background Current guidelines in inflammatory bowel disease (IBD) advocate for endoscopic biopsies to confirm cytomegalovirus (CMV) colitis by means of immunohistochemistry (IHC) or tissue polymerase chain reaction (tPCR). Clinical usefulness of whol
Autor:
X Serra-Ruiz, H D G Claudia, L Mayorga Ayala, V Robles Alonso, E Céspedes Martínez, F Casellas, M Miarons, S Garcia-Garcia, Z Pérez Martínez, E Oller, N Borruel Sainz
Publikováno v:
Journal of Crohn's and Colitis. 17:i313-i314
Background Ustekinumab (UST), an inhibitor of the p40 subunit of interleukins 12 and 23, is an effective treatment for patients with Crohn’s disease (CD) and ulcerative colitis (UC). There is limited data on therapeutic outcomes and UST trough leve
Publikováno v:
Journal of Crohn's and Colitis. 17:i912-i913
Background Vedolizumab (VDZ) is a gut-selective, anti-lymphocyte trafficking drug inhibiting α4β7-integrin approved for treatment of moderately to severely Crohn's disease (CD) and ulcerative colitis (UC). Methods This was a retrospective cohort st
Publikováno v:
Journal of Crohn's and Colitis. 17:i740-i741
Background Vedolizumab (VDZ) is a gut-selective, anti- lymphocyte trafficking drug inhibiting α4β7-integrin approved for treatment of moderately to severely Crohn's disease (CD) and ulcerative colitis (UC). Methods Medical charts from CD patients w
Publikováno v:
Revista Espanola de Enfermedades Digestivas, Vol 101, Iss 3, Pp 163-167 (2009)
Background: the treatment of severe ulcerative colitis (UC) flares includes measures such as hospitalization and intravenous steroids. Despite this, a quarter of patients are refractory to treatment. Given the availability of new therapeutic strategi
Externí odkaz:
https://doaj.org/article/b0237939dadd41da8a768a2992cc8bb3
Publikováno v:
Revista Espanola de Enfermedades Digestivas, Vol 100, Iss 1, Pp 1-4 (2008)
Externí odkaz:
https://doaj.org/article/1e707462a26a45618381a3c53d2db8d1
Publikováno v:
Revista Espanola de Enfermedades Digestivas, Vol 99, Iss 9, Pp 511-519 (2007)
Introducción: la medida de la calidad de vida relacionada con la salud (CVRS) tiene una reconocida importancia en la evaluación, el manejo y el seguimiento de la enfermedad inflamatoria intestinal. El instrumento de medida más utilizado es la vers
Externí odkaz:
https://doaj.org/article/9ad25d508ad84a49bdb576c191153248